August 7, 2023 7:41am
Earnings are still a non-stimulus as investors shift focus to the release of July consumer and producer price index data later in the week
News: Sage Therapeutics (SAGE closed +$0.09, Friday aftermarket of -$16.22 or -44.9%) Zuranolone, a new drug co-developed with Biogen (BIIB), scored an FDA approval late Friday — but the approval was only for postpartum depression, not major depressive disorder. SAGE/BIIB had applied to market the drug as a treatment for both.
Earnings: AxoGen (AXGN) and Sage Therapeutics (SAGE)
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Never leave an investor uninformed!
Pre-open Indication: 1 Negative Indication
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday
Dow futures are UP +0.14% or (+49 point), S&P futures are UP +0.24% or (+11 points) and NASDAQ futures are UP +0.39% or (+60 points) early in the pre-open – so far
Stock futures rose Monday, August 7, 2023
European stock markets were choppy,
Asia-Pacific markets largely fell.
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes fizzled on Friday, as the Dow closed DOWN -150.27 points (-0.43%), the S&P closed DOWN -23.86 points (-0.53%) while the Nasdaq closed DOWN -50.48 points (-0.36%)
All the major indexes finished the week with losses; the Nasdaq dived -2.9% and S&P dropped -2.3%, while the Dow followed down -1.1%.
Economic Data Docket: July consumer and producer price index data later in the week
Friday’s (8/4) RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector slowly fades after earnings’ LPS (loss-per-share) reports.” … https://www.regmedinvestors.com/articles/13065
Ebb and flow:
Q3: August – 4 negative closes
· July - 1 holiday, 12 positive and 8 negative close
Q2/23 -
· June -1 Holiday, 8 negative and 11 positive closes
· May – 10 negative and 12 positive closes
· April ended - 1 holiday, 8 positive close and 11 negative closes
Q1/23 –-
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
I am parsing on making any forecast, let the sector roll, stroll or tumble; however,
Negative Indication:
Friday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Sage Therapeutics (SAGE) closed up +$0.09 with a negative -$16.20 or -44.9% pre-open indication
The BOTTOM LINE:
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all, as I try to keep it simple and short!
The cell and gene therapy sector suffered 4 negative closed so far in this early August.
The sector could be at an inflection point, for good or ill. With the uptrend "under pressure," investors should be cautious about new buys. But it is an excellent time to be looking for promising stocks.
You could nibble on some new buys, or add a few more shares to winning positions, perhaps trimming some laggards.
SOME equities COULD be flashing buy signals post earnings’ release … and IF you take action, do so gradually. The past few weeks of up-and-down trading, including Friday, have meant that many recent buys have quickly struggled.
Earnings … TODAY … AxoGen (AXGN) on Monday
Filed so far: uniQure NV (QURE) and MiMedx MDXG), Vericel (VCEL), Blueprint Medicine (BPMC), Editas Medicine (EDIT) and REGENXBIO (RGNX), Voyager Therapeutics (VYGR), Ultragenyx (RARE), Intellia Therapeutics (NTLA), Cellectis SA (CLLS) …
· Questions are …consensus and revenue beats and misses??
RegMed Investors (RMi) Research Note: Q2/23 net losses earnings, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/13058
There's nothing wrong with standing pat in the short run, holding on to sizable existing exposure.
I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
